Toward a treatment goal framework for emerging therapies in IgA nephropathy: Implications for future research

The therapeutic landscape for IgA nephropathy (IgAN) is evolving rapidly, with new agents and mechanistic insights reshaping how clinicians and investigators think about disease modification, biomarker interpretation, and treatment strategies. The recent KDIGO IgAN interim commentary1 builds a structured framework for organizing therapies according to the treatment goals they address. These goals include stopping the synthesis of pathogenic forms of IgA/IgA-containing immune complexes (Hits 1-3 of IgAN pathogenesis), stopping IgA/IgA-containing immune complex-mediated kidney injury (Hit 4), and managing the generic responses to IgAN-induced nephron loss.